In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Europe to personalise prevention of second heart attacks

Public Health
Risk Factors and Prevention

Sophia Antipolis, 19 February 2020:  A major EU-funded project to personalise prevention of second heart attacks is being launched today by the European Society of Cardiology (ESC).

Cardiovascular disease (CVD) is the top cause of death in Europe and worldwide, accounting for 47% of deaths in women and 39% of deaths in men.1 CVD costs the EU more than €210 billion a year,2 a sum expected to escalate with an ageing population and the cost of novel therapies.

The new project, CoroPrevention, has nearly €20 million of Horizon 2020 funding to discover the lifestyle improvements and medications needed by individual patients with coronary heart disease to prevent another cardiovascular event. Clinical centres were selected mainly from countries with suboptimal programmes, according to an ESC survey.

The project features a randomised clinical trial in high risk patients with coronary heart disease identified with a new set of risk markers. The trial will test a novel, personalised prevention programme designed by the European Association of Preventive Cardiology (EAPC), a branch of the ESC. Tailored approaches will take patient preferences for behaviour change into account. Nurses and mobile apps will provide personalised coaching on exercise, diet, improving sleep, mindfulness, stress reduction, reducing screen time and sitting, quitting smoking, moderating alcohol intake, and adhering to preventive medications.

Professor Reijo Laaksonen, Project Lead from Tampere University and Zora Biosciences said: “The prevention programme’s objective is be the patient’s guiding companion for life, helping them maintain long-term behaviour changes that preserve their health. We expect it to reduce premature deaths and severe disabilities in patients with coronary heart disease in Europe.”

Patient workshops will be held at recruiting sites to share experiences of participating in the trial and create ambassadors to communicate with new participants. The ESC Patient Forum will share the learning from these workshops across study sites to optimise patient engagement.

Cost-effectiveness will also be assessed. Professor Paul Dendale, EAPC President, said: “The project will establish a cutting edge, economically sustainable personalised prevention programme for use throughout Europe. Regulators, policy makers and payers will receive compelling evidence for the economic and social value of preventing cardiovascular disease. We estimate that the ESC designed programme will reduce the cardiovascular event rate by 25% in high-risk patients – with annual savings of tens of billions of euros to the EU.”


Notes to editor

Authors: ESC Press Office
Tel: +33 (0)4 89 87 20 85

Mobile: +33 (0)7 8531 2036

Follow us on Twitter @ESCardioNews 



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 848056.



1ESC Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41:12-85. doi:10.1093/eurheartj/ehz859.



About the European Association of Preventive Cardiology

The European Association of Preventive Cardiology (EAPC) is a branch of the ESC. Its mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.


About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.